After two challenging years, characterized by declining valuations and a fall-off in new company formations, optimism is returning to the investment sector for medical technology, according to Thomas Robinson and Mark Yowe in "Beyond the bust."
As funding starts to flow again, what leadership and management issues face medical technology companies today and in the future?
In "The first 100 days," Mark Broer and Phil Le Goff interview Göran Ando of UK-based Celltech Group talks about his path to the CEO office. Ando’s route to the top was hardly the norm but proves an executive can be successful regardless of background if surrounded by a team that complements his or her skills.
We interviewed Ando, a medical doctor who worked in development at one of the largest US pharmaceutical companies, about his transition and the issues and considerations facing a new CEO. He talks about his initial priorities for the company and the unique opportunity for making significant change during the “honeymoon” period of a CEO’s first 100 days. Ando also shares his perspective on the challenges and opportunities facing the biotechnology industry in Europe.
For information about copying, distributing and displaying this work, contact permissions@spencerstuart.com.
(PDF - 541K)